Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies

被引：0
|
作者：
Xenofon Baraliakos
Filip Van den Bosch
Pedro M. Machado
Lianne S. Gensler
Helena Marzo-Ortega
Bintu Sherif
Erhard Quebe-Fehling
Brian Porter
Corine Gaillez
Atul Deodhar
机构：
[1] Ruhr-University Bochum,Rheumazentrum Ruhrgebiet Herne
[2] Ghent University,Department of Internal Medicine and Pediatrics
[3] VIB Center for Inflammation Research,Department of Rheumatology
[4] University College London Hospitals NHS Foundation Trust,Department of Rheumatology, Northwick Park Hospital
[5] London North West University Healthcare NHS Trust,Centre for Rheumatology and Department of Neuromuscular Diseases
[6] University College London,Department of Medicine/Rheumatology
[7] University of California,NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds Institute of Rheumatic and Musculoskeletal Medicine
[8] San Francisco,undefined
[9] University of Leeds,undefined
[10] RTI Health Solutions,undefined
[11] Novartis Pharma AG,undefined
[12] Novartis Pharmaceuticals Corporation,undefined
[13] Oregon Health and Science University,undefined
来源：
Rheumatology and Therapy | 2021年 / 8卷
关键词：
Ankylosing spondylitis; Axial spondyloarthritis; Biologics; Interleukin-17; Low disease activity; Patient-reported outcomes; Remission; Secukinumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：273 / 288
页数：15
相关论文
共 50 条
  • [21] SECUKINUMAB DEMONSTRATES CONSISTENT SAFETY OVER LONG-TERM EXPOSURE UP TO THREE YEARS IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: POOLED ANALYSIS OF THREE PHASE III TRIALS
    Barkham, Nick
    Deodhar, Atul
    Baraliakos, Xenofon
    Marzo-Ortega, Helena
    Sieper, Joachim
    Andersson, Mats
    Porters, Brian
    Fox, Todd
    RHEUMATOLOGY, 2018, 57
  • [22] SECUKINUMAB DEMONSTRATES RAPID AND SUSTAINED EFFICACY IN ANKYLOSING SPONDYLITIS PATIENTS WITH NORMAL OR ELEVATED BASELINE C-REACTIVE PROTEIN LEVELS: POOLED ANALYSIS OF TWO PHASE 3 STUDIES
    Barkham, Nick
    Braun, Juergen
    Sieper, Joachim
    Landewe, Robert
    Baraliakos, Xenofon
    Miceli-Richard, Corinne
    Quebe-Fehling, Erhard
    Porter, Brian
    Gandhi, Kunal
    van der Heijde, Desiree
    RHEUMATOLOGY, 2019, 58 : 153 - 154
  • [23] Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
    Laura C. Coates
    Johan K. Wallman
    Dennis McGonagle
    Georg A. Schett
    Iain B. McInnes
    Philip J. Mease
    Lawrence Rasouliyan
    Erhard Quebe-Fehling
    Darren L. Asquith
    Andreas E. R. Fasth
    Luminita Pricop
    Corine Gaillez
    Arthritis Research & Therapy, 21
  • [24] Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
    Coates, Laura C.
    Wallman, Johan K.
    McGonagle, Dennis
    Schett, Georg A.
    McInnes, Iain B.
    Mease, Philip J.
    Rasouliyan, Lawrence
    Quebe-Fehling, Erhard
    Asquith, Darren L.
    Fasth, Andreas E. R.
    Pricop, Luminita
    Gaillez, Corine
    ARTHRITIS RESEARCH & THERAPY, 2019, 21 (01)
  • [25] Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
    Braun, Juergen
    Deodhar, Atul
    Landewe, Robert
    Baraliakos, Xenofon
    Miceli-Richard, Corinne
    Sieper, Joachim
    Quebe-Fehling, Erhard
    Martin, Ruvie
    Porter, Brian
    Gandhi, Kunal K.
    van der Heijde, Desiree
    Gallagher, John
    Maity, Niladri
    Pillai, Neeta
    RMD OPEN, 2018, 4 (02):
  • [26] Secukinumab Provides Early and Sustained Improvements in Health-Related Quality of Life in Patients with Ankylosing Spondylitis: A Pooled Analysis from the Secukinumab Phase 3 Trial Program
    Deodhar, Atul A.
    Boonen, Annelies
    Ferraccioli, Gianfranco
    van Den Bosch, Filip
    Martinez, David
    Porter, Brian
    Shete, Abhijit
    Scheuer, Nicolas
    Gilloteau, Isabelle
    Strand, Vibeke
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [27] SECUKINUMAB PROVIDED SIMILAR EFFICACY IN MALES AND FEMALES WITH ACTIVE ANKYLOSING SPONDYLITIS OVER 52 WEEKS: POST HOC POOLED ANALYSIS OF THE MEASURE TRIALS
    van der Horst-Bruinsma, Irene
    Richard, Corinne Miceli
    Braun, Juergen
    Bao, Weibin
    Porter, Brian
    Pournara, Effie
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 897 - 898
  • [28] Shift Analysis of Spinal Radiographic Progression after 2 Years of Secukinumab in Ankylosing Spondylitis - Detailed Results from a Phase 3 Trial
    Baraliakos, Xenofon
    Braun, Juergen
    Widmer, Albert
    Das Gupta, Ayan
    Readie, Aimee
    Porter, Brian
    Gaillez, Corine
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [29] Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3
    Karel Pavelka
    Alan Kivitz
    Eva Dokoupilova
    Ricardo Blanco
    Marco Maradiaga
    Hasan Tahir
    Luminita Pricop
    Mats Andersson
    Aimee Readie
    Brian Porter
    Arthritis Research & Therapy, 19
  • [30] Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3
    Pavelka, Karel
    Kivitz, Alan
    Dokoupilova, Eva
    Blanco, Ricardo
    Maradiaga, Marco
    Tahir, Hasan
    Pricop, Luminita
    Andersson, Mats
    Readie, Aimee
    Porter, Brian
    ARTHRITIS RESEARCH & THERAPY, 2017, 19
12345